{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:41:37Z","timestamp":1791326497674,"version":"4.3.1"},"reference-count":134,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014448","name":"Govan Mbeki Research and Development Centrem, University of Fort Hare","doi-asserted-by":"publisher","award":["GMRDC"],"award-info":[{"award-number":["GMRDC"]}],"id":[{"id":"10.13039\/100014448","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["SAMRC"],"award-info":[{"award-number":["SAMRC"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metastatic bone cancer occurs in every type of cancer but is prevalent in lung, breast, and prostate cancers. These metastases can cause extensive morbidity, including a range of skeletal-related events, often painful and linked with substantial hospital resource usage. The treatment used is a combination of chemotherapy and surgery. However, anticancer drugs are still limited due to severe side effects, drug resistance, poor blood supply, and non-specific drug uptake, necessitating high toxic doses. Bisphosphonates are the main class of drugs utilized to inhibit metastatic bone cancer. It is also used for the treatment of osteoporosis and other bone diseases. However, bisphosphonate also suffers from serious side effects. Thus, there is a serious need to develop bisphosphonate conjugates with promising therapeutic outcomes for treating metastatic bone cancer and osteoporosis. This review article focuses on the biological outcomes of designed bisphosphonate-based conjugates for the treatment of metastatic bone cancer and osteoporosis.<\/jats:p>","DOI":"10.3390\/ijms22136869","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T22:24:57Z","timestamp":1624832697000},"page":"6869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer"],"prefix":"10.3390","volume":"22","author":[{"given":"Zintle","family":"Mbese","sequence":"first","affiliation":[{"name":"Department of Chemistry, Alice Campus, University of Fort Hare, Alice 5700, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessing A.","family":"Aderibigbe","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Alice Campus, University of Fort Hare, Alice 5700, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"172773","DOI":"10.1016\/j.ejphar.2019.172773","article-title":"Bisphosphonates\u2014much more than only drugs for bone diseases","volume":"866","author":"Jewula","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","article-title":"Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue","volume":"4","author":"Toussaint","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: From bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: Molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Design."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.molmed.2004.05.007","article-title":"Bisphosphonates: New therapeutic agents for the treatment of bone tumors","volume":"10","author":"Heymann","year":"2004","journal-title":"Trends Mol. Med."},{"key":"ref_6","first-page":"396","article-title":"Bisphosphonates and oral pathology I","volume":"11","author":"Fresco","year":"2006","journal-title":"Gen. Prev. Asp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1939-1676.2004.tb02593.x","article-title":"Bisphosphonates and cancer","volume":"18","author":"Milner","year":"2004","journal-title":"J. Vet. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bigi, A., and Boanini, E. (2018). Calcium phosphates as delivery systems for bisphosphonates. J. Funct. Biomater., 9.","DOI":"10.3390\/jfb9010006"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kocijan, R., Klaushofer, K., and Misof, B.M. (2020). Osteoporosis therapeutics 2020. Snake Venoms, 397\u2013422.","DOI":"10.1007\/164_2020_373"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ddr.10071","article-title":"Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption","volume":"55","author":"Green","year":"2002","journal-title":"Drug Dev. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcms.2005.07.007","article-title":"Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?","volume":"33","author":"Lenz","year":"2005","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S8756-3282(03)00112-1","article-title":"Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal","volume":"33","author":"Bagger","year":"2003","journal-title":"Bone"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for paget\u2019s disease","volume":"353","author":"Reid","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3322\/caac.21489","article-title":"Hypercalcemia and cancer: Differential diagnosis and treatment","volume":"68","author":"Zagzag","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1019905111666","article-title":"The effect of the bisphos-phonate ibandronate on breast cancer metastasis to visceral organs","volume":"75","author":"Michigami","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001813-200502000-00001","article-title":"Ibandronate in metastatic bone disease: A review of preclinical data","volume":"16","author":"Bauss","year":"2005","journal-title":"Anti-Cancer Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose\u2013response study","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00586-012-2231-1","article-title":"Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: Preliminary report","volume":"21","author":"Tamburrelli","year":"2012","journal-title":"Eur. Spine J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jormas.2019.04.003","article-title":"Effects of bisphosphonate treatment on mandibular condyle tissues of temporo-mandibular joint: A stereological study","volume":"120","author":"Gonen","year":"2019","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and benefits of bisphosphonate therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"ref_22","unstructured":"Ganesan, K., Bansal, P., Goyal, A., and Roane, D. (2021, April 10). Bisphosphonate, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470248\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1156","DOI":"10.1097\/MD.0000000000001156","article-title":"The efficacy of parathyroid hormone analogues in combination with bisphosphonates for the treatment of osteoporosis: A meta-analysis of randomized controlled trials","volume":"94","author":"Li","year":"2015","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1359\/jbmr.2000.15.5.936","article-title":"Selective drug delivery system to bone: Small peptide (Asp)6 conjugation","volume":"15","author":"Kasugai","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: Denosumab vs bisphosphonates for the treat-ment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00586-003-0622-z","article-title":"Bisphosphonates in osteoporosis","volume":"12","author":"Fleisch","year":"2003","journal-title":"Eur. Spine J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1517\/17425247.2015.1021679","article-title":"Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering","volume":"12","author":"Ossipov","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1590\/S0004-27302006000400023","article-title":"Transplantation osteoporosis","volume":"50","author":"Kulak","year":"2006","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone turnover markers in the diagnosis and monitoring of metabolic bone disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_31","first-page":"183","article-title":"Osteoporosis in chronic pancreatitis outpatients associates with several risk factors","volume":"19","author":"Kuhlmann","year":"2018","journal-title":"Pancreas"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/1874844901603010056","article-title":"Physiologic activity of bisphosphonates\u2014Recent advances","volume":"3","author":"Chmielewska","year":"2016","journal-title":"Open Pharm. Sci. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0039-128X(00)00148-3","article-title":"Synthesis and biological activities of a new series of secosteroids: Vitamin D phosphonate hybrids","volume":"66","author":"Steinmeyer","year":"2001","journal-title":"Steroids"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1211\/0022357001773652","article-title":"Tissue distribution and pharmacological potential of SM-16896, a novel oestrogen-bisphosphonate hybrid compound","volume":"52","author":"Tsushima","year":"2000","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/10717544.2017.1422295","article-title":"Bone-targeted methotrexate\u2013alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo","volume":"25","author":"Xie","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jlcr.3532","article-title":"Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique","volume":"60","author":"Motaleb","year":"2017","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","journal-title":"Bone Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e016022","DOI":"10.1136\/bmjopen-2017-016022","article-title":"Survival after bone metastasis by primary cancer type: A Danish population-based cohort study","volume":"7","author":"Svensson","year":"2017","journal-title":"BMJ Open"},{"key":"ref_39","first-page":"311","article-title":"In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease","volume":"19","author":"Kanakis","year":"2005","journal-title":"Vivo"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e000037","DOI":"10.1136\/esmoopen-2016-000037","article-title":"Diagnosis and treatment of bone metastasis: Comprehensive guideline of the Japanese society of medical oncology, Japanese orthopedic association, Japanese urological association, and Japanese society for radiation oncology","volume":"1","author":"Shibata","year":"2016","journal-title":"ESMO Open"},{"key":"ref_41","unstructured":"Rudnick-Glick, S., Tal, N., Corem-Slakman, E., Grinberg, I., Gluz, E., and Margel, S. (2020, October 01). Synthesis and Characterization of Bisphos-phonate Nano\/Micro-Particles for Bone Cancer Targeting and Therapy. Available online: http:\/\/uilis.unsyiah.ac.id\/oer\/files\/original\/063e69a06ce12330abacb6f43ad122e6.pdf."},{"key":"ref_42","first-page":"2713","article-title":"Multifunctional materials for bone cancer treat-ment","volume":"9","author":"Marques","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2967\/jnumed.112.105338","article-title":"Oncologic PET\/MRI, part 1: Tumors of the brain, head and neck, chest, abdomen, and pelvis","volume":"53","author":"Buchbender","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2013.07.036","article-title":"Selection of bone me-tastasis seeds by mesenchymal signals in the primary tumor stroma","volume":"154","author":"Zhang","year":"2013","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ccr.2013.09.008","article-title":"Tumor-induced osteo-clast miRNA changes as regulators and biomarkers of osteolytic bone metastasis","volume":"24","author":"Ell","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_46","first-page":"85840","article-title":"Interstitial ultrasound ablation of tumors within or adjacent to bone: Contributions of preferential heating at the bone surface. In Energy-based Treatment of Tissue and Assessment VII","volume":"8584","author":"Scott","year":"2013","journal-title":"Int. Soc. Opt. Photonics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.semnuclmed.2015.10.012","article-title":"Treatment of metastatic bone disease and the emerging role of radium-223","volume":"46","author":"Coleman","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.taap.2014.01.009","article-title":"Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment","volume":"275","author":"Park","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/imj.13502","article-title":"Bisphosphonate guidelines for treatment and prevention of myeloma bone disease","volume":"47","author":"Lee","year":"2017","journal-title":"Intern. Med. J."},{"key":"ref_50","first-page":"4299","article-title":"Cytostatic activity of a 5-Fluoro-2\u2032-deoxyuridine\u2013Alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fi-broblast cell lines","volume":"32","author":"Weinreich","year":"2012","journal-title":"AntiCancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bmcl.2007.11.029","article-title":"Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation","volume":"18","author":"Erez","year":"2008","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.bmcl.2013.09.043","article-title":"Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma","volume":"23","author":"Agyin","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1248\/cpb.59.710","article-title":"Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor","volume":"59","author":"Nakatake","year":"2011","journal-title":"Chem. Pharm. Bull."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","article-title":"The relationship between the chemistry and biological activity of the bisphosphonates","volume":"49","author":"Ebetino","year":"2011","journal-title":"Bone"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5188\/ijsmer.20.45","article-title":"Facile synthesis of bisphosphonates","volume":"20","author":"Kunda","year":"2014","journal-title":"Int. J. Soc. Mater. Eng. Resour."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.apradiso.2004.10.004","article-title":"188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases","volume":"62","author":"Mercer","year":"2005","journal-title":"Appl. Radiat. Isot."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphos-phonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14302\/issn.2576-6694.jbbs-19-2953","article-title":"Assessment of anticancer effect of alendronate in breast cancer: An in vitro study","volume":"2","author":"Ilyas","year":"2019","journal-title":"J. Biotechnol. Biomed. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00520-005-0913-5","article-title":"Bisphosphonates for malignancy-related bone disease: Current status, future developments","volume":"14","author":"Body","year":"2006","journal-title":"Support. Care Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1479-5876-11-303","article-title":"Basic research and clinical applications of bisphosphonates in bone disease: What have we learned over the last 40 years?","volume":"11","author":"Xu","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1345\/aph.1E357","article-title":"Discovery, clinical development, and therapeutic uses of bisphosphonates","volume":"39","author":"Licata","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001813-200501000-00002","article-title":"Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion","volume":"16","author":"Woodward","year":"2005","journal-title":"Anti-Cancer Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/sj.bjc.6600476","article-title":"The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro","volume":"87","author":"Riebeling","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/01.COC.0000074165.90133.40","article-title":"Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines","volume":"26","author":"Witters","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2004.06.003","article-title":"Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines","volume":"47","author":"Matsumoto","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_68","first-page":"6538","article-title":"Bisphosphonates inhibit angio-genesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1601119","DOI":"10.1002\/adhm.201601119","article-title":"Bisphosphonate-functionalized imaging agents, anti-tumor agents and nanocarriers for the treatment of bone cancer","volume":"6","author":"Nadar","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proin-flammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/02841860701233435","article-title":"The use of bisphosphonates in cancer patients","volume":"46","author":"Wu","year":"2007","journal-title":"Acta Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10717544.2013.870259","article-title":"Bisphosphonates: Therapeutics potential and recent advances in drug delivery","volume":"22","author":"Fazil","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJM200304103481521","article-title":"Severe hypocalcemia after intravenous bisphosphonate therapy in occult Vitamin D deficiency","volume":"348","author":"Rosen","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_75","first-page":"1476","article-title":"Does bisphosphonate treatment reduce the risk of future cancer?","volume":"29","author":"Pazianas","year":"2018","journal-title":"Oncology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive Activity","volume":"65","author":"Ebetino","year":"2005","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3748\/wjg.v22.i3.906","article-title":"Bisphosphonates as potential adjuvants for patients with cancers of the digestive system","volume":"22","author":"Ang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12609-018-0295-6","article-title":"Bone-modifying agents in early-stage and advanced breast cancer","volume":"10","author":"Heeke","year":"2018","journal-title":"Curr. Breast Cancer Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/1078-0432.CCR-16-0547","article-title":"Oral bisphosphonates and improved survival of breast cancer","volume":"23","author":"Rennert","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ijc.28965","article-title":"Bisphosphonates in breast cancer","volume":"137","author":"Mathew","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_83","first-page":"2526","article-title":"Bone targeted therapies in advanced breast cancer","volume":"147","author":"Biskup","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/0004563011901037","article-title":"Bisphosphonates: An overview with special reference to alendronate","volume":"38","author":"Vasikaran","year":"2001","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Adjei, I.M., Temples, M.N., Brown, S.B., and Sharma, B. (2018). Targeted nanomedicine to treat bone metastasis. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040205"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s10637-011-9688-3","article-title":"Cytotoxicity of the new antimetabo-lite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay","volume":"30","author":"Schott","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/jbmr.3012","article-title":"Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts: In vivo assessment of 5-fluorodeoxyuridine-alendronate in a preclinical model of breast cancer bone metastases","volume":"32","author":"Schem","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1721727X0500300201","article-title":"Bisphosphonates treatment in metastatic prostate cancer","volume":"3","author":"Berardinelli","year":"2005","journal-title":"Eur. J. Inflamm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"462","DOI":"10.12968\/ijpn.2006.12.10.22118","article-title":"Skeletal complications and the use of bisphosphonates in metastatic prostate cancer","volume":"12","year":"2006","journal-title":"Int. J. Palliat. Nurs."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1525832","article-title":"The current role of osteoclast inhibitors in patients with prostate cancer","volume":"2018","author":"Kozyrakis","year":"2018","journal-title":"Adv. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11912-006-0023-7","article-title":"The role of bisphosphonates in the management of prostate cancer","volume":"8","author":"Saad","year":"2006","journal-title":"Curr. Oncol. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Body, J.J., von Moos, R., Niepel, D., and Tombal, B. (2018). Hypocalcaemia in patients with prostate cancer treated with a bisphospho-nate or denosumab: Prevention supports treatment completion. BMC Urol., 18.","DOI":"10.1186\/s12894-018-0393-9"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hayes, A.R., Brungs, D., and Pavlakis, N. (2018). Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191455"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/CMAR.S40151","article-title":"Future of bisphosphonates and denosumab for men with advanced prostate cancer","volume":"6","author":"Iranikhah","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2018.04.014","article-title":"The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer","volume":"68","author":"Saad","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_96","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","volume":"12","author":"Macherey","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-13-2652","article-title":"An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer","volume":"74","author":"Araujo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_98","first-page":"204","article-title":"Bisphosphonates in metastatic prostate cancer","volume":"5","author":"Khan","year":"2003","journal-title":"Rev. Urol."},{"key":"ref_99","first-page":"4559","article-title":"Adhesion of breast cancer cells to extracellular matrices is inhibited by zoledronic acid and enhanced by aberrant Ras signalling","volume":"22","author":"Pickering","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of \u03b3\u03b4 T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/156800909789760285","article-title":"Cutting the limits of aminobisphosphonates: New strategies for the potentiation of their anti-tumour effects","volume":"9","author":"Marra","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1038\/sj.onc.1207814","article-title":"The farnesyl transferase inhibitor R115777 (Zarnestra\u00ae) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa\u00ae) and Pamidronate","volume":"23","author":"Caraglia","year":"2004","journal-title":"Oncogene"},{"key":"ref_105","first-page":"1","article-title":"Bisphosphonates and cancer: What opportunities from nanotechnology?","volume":"2013","author":"Misso","year":"2013","journal-title":"J. Drug Deliv."},{"key":"ref_106","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphos-phonate use in patients with lung cancer and bone metastases: Recommendations of a European expert panel","volume":"4","author":"Eberhardt","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1093\/annonc\/mds009","article-title":"Bone matters in lung cancer","volume":"23","author":"Brodowicz","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Akoury, E., Luna, A.S.R.G., Ahangar, P., Gao, X., Zolotarov, P., Weber, M.H., and Rosenzweig, D.H. (2019). Anti-tumor effects of low dose zoledronate on lung cancer-induced spine metastasis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8081212"},{"key":"ref_110","first-page":"349","article-title":"Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017","volume":"11","author":"Nakahara","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2014.00146","article-title":"Targeted treatments of bone metastases in patients with lung cancer","volume":"4","author":"Hirsh","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_112","first-page":"1","article-title":"Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00520-012-1563-z","article-title":"Bisphosphonates in the treat-ment of patients with lung cancer and metastatic bone disease: A systematic review and meta-analysis","volume":"20","author":"Shah","year":"2012","journal-title":"Support Care Cancer."},{"key":"ref_114","first-page":"5380","article-title":"Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice","volume":"9","author":"Yano","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Koshimune, R., Aoe, M., Toyooka, S., Hara, F., Ouchida, M., Tokumo, M., Sano, Y., Date, H., and Shimizu, N. (2007). Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-8"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.nucmedbio.2006.06.004","article-title":"A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer","volume":"33","author":"Angelov","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-008-0728-y","article-title":"188Re-labelled gemcitabine\/bisphosphonate (Gem\/BP): A multi-functional, bone-specific agent as a potential treatment for bone metastases","volume":"35","author":"Mercer","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.bmc.2011.04.015","article-title":"N4-[Alkyl-(hydroxyphosphono) phospho-nate]-cytidine\u2014New drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate)","volume":"19","author":"Schott","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"57932","DOI":"10.18632\/oncotarget.10773","article-title":"Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","first-page":"1","article-title":"Role of Bisphosphonate (Bps) in Breast Cancer: An Update","volume":"1","author":"Kumar","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"87373","DOI":"10.18632\/oncotarget.13570","article-title":"Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth in-hibitory effects of bisphosphonates in vitro and in vivo","volume":"7","author":"Sandholm","year":"2016","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000368710","article-title":"Bone-targeted therapy in metastatic breast cancer\u2014All well-established knowledge?","volume":"9","author":"Gampenrieder","year":"2014","journal-title":"Breast Care"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br. J. Cancer."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1178223419843501","DOI":"10.1177\/1178223419843501","article-title":"Bone-targeted agents in breast cancer: Do we now have all the answers?","volume":"13","author":"Ottewell","year":"2019","journal-title":"Breast Cancer Basic Clin. Res."},{"key":"ref_125","first-page":"267","article-title":"Mechanisms of action of bisphosphonates in oncology: A scientific concept evolving from antiresorptive to anticancer activities","volume":"2","year":"2013","journal-title":"BoneKEy Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/bcr1543","article-title":"In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells","volume":"8","author":"Ural","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_127","first-page":"1246","article-title":"Antiproliferative and antimigratory activities of bisphosphonates in human breast cancer cell line MCF-7","volume":"18","author":"Buranrat","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_128","first-page":"913","article-title":"Inhibition of survivin is associated with zoledronic acid-induced apoptosis of prostate cancer cells","volume":"36","author":"Fragni","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eursup.2004.08.008","article-title":"Preclinical profile of zoledronic acid in prostate cancer models","volume":"3","author":"Green","year":"2004","journal-title":"Eur. Urol. Suppl."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e2014","DOI":"10.1097\/MD.0000000000002014","article-title":"Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in the survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5301\/JBM.5000022","article-title":"Bone markers for monitoring efficacy in patients with bone metastases receiving zoledronic acid: A review of published data","volume":"28","author":"Huang","year":"2013","journal-title":"Int. J. Biol. Markers"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3892\/or.2016.4741","article-title":"Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations","volume":"35","author":"Feng","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1427306","DOI":"10.1080\/23312025.2018.1427306","article-title":"Effects of alendronate and interferon-\u03b3 on bone cancer cells in vitro","volume":"4","author":"Barone","year":"2018","journal-title":"Cogent Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:38Z","timestamp":1760163878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":134,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22136869"],"URL":"https:\/\/doi.org\/10.3390\/ijms22136869","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]}}}